Publications
Individual, Health System, and Societal Impacts of Anti-seizure Medicine Use During Pregnancy
23 January 2024
Explore the implications of in utero exposure to anti-seizure medications (ASMs), the heightened risks of developmental problems and physical disabilities. The economic impact associated with conditions like epilepsy, stressing the urgent need for detailed risk profiles and data collection to guide interventions and reduce the societal costs linked to ASM use during pregnancy.
The Dynamics of Drug Shortages
9 January 2024
Drug shortages are an industry-wide problem. Numerous factors may be considered as contributing to drug shortages across the globe. In this report, we discuss the global issue of drug shortages, summarise the main reasons for shortages as presented in the literature and our quantitative analysis. Finally, we provide recommendations for policy makers.
2022 OHE Annual Report to the Charity Commission
30 November 2023
This is the sixth report to the Charity Commission for England and Wales since becoming a registered charity in December 2016.
Capturing the Broader Value of Antibiotics
23 November 2023
The value of antibiotics often extends beyond what HTA captures. The STEDI framework aims to capture that broader value and our report outlines a roadmap to realising its full potential.
Innovation for Health System Efficiency and Improvement
20 November 2023
In this report, commissioned and funded by Gilead, we explore the role of innovation in developing healthcare system efficiency amid post-pandemic challenges.
Proposals for a Novel UK Antimicrobial Subscription Model: How Will Antibiotic Innovation be Scored?
8 November 2023
NHS England conducted a public consultation on a ‘volume-delinked model’ subscription approach to address the market failure hindering the development of urgently needed antibiotics.
Proposals for a Novel UK Antimicrobial Subscription Model: The Investor Perspective
2 November 2023
New antibiotics are urgently needed, but their development is hindered by market failure. A ‘volume-delinked model’ subscription approach has been suggested to overcome this market failure, providing compensation regardless of sales volume.
Reimagining Prevention for a Healthier, More Prosperous Society
12 October 2023
In this report, we highlight the significance of prevention as a cost-effective and often cost-saving investment for public sector resources. Prevention, covering primary, secondary, and tertiary measures, can help to reduce ill health, improve healthcare capacity, and increase wider economic growth.
NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?
18 September 2023
In this report, we explore the potential impact of the National Institute of Health and Care Excellence (NICE) decision outcomes on healthcare decision-making in 12 countries across the globe (Australia, Brazil, Canada, France, Italy, Israel, Japan, South Korea, Poland, Saudi Arabia, Sweden, and the United Arab Emirates). We used quantitative and qualitative methods to estimate the level of impact and potential underlying mechanisms.